Indopedia All Things Marijuana
Press Release-TEL AVIV, Israel, June 5, 2018 — Therapix Biosciences Ltd., a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced that on June 05, 2018, the first subject was enrolled for its Phase IIa, sponsor-initiated clinical trial using the Company’s cannabinoid-based technology THX-110 for Obstructive Sleep Apnea (OSA), at Assuta Medical Center, the largest private hospital network in Israel.
About The Weed Blog
Since its inception, TWB has been based in activism and the mobilization and movements for marijuana policy reform happening around the country. It was created for one purpose: to facilitate a constructive conversation about marijuana in America. This includes both medical and recreational marijuana policy, as well as the marijuana industry and culture.
Related Articles
30 Day Weed Tolerance Break Challenge
January 24, 2023
Most reported substance use among adolescents held steady in 2022
December 15, 2022
The Best Cannabis Holiday Gifts for 2022
December 6, 2022